Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cystic fibrosis | D003550 | EFO_0000390 | E84 | 1 | 2 | — | — | — | 3 |
Fibrosis | D005355 | — | — | — | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Drug common name | GALICAFTOR |
INN | galicaftor |
Description | Galicaftor is a small molecule pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Small molecule |
Drug class | cystic fibrosis transmembrane regulator (CFTR) protein modulators |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | O=C(O)c1ccc([C@H]2C[C@@H](NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c3ccc(OC(F)F)cc3O2)cc1 |
PDB | — |
CAS-ID | 1918143-53-9 |
RxCUI | — |
ChEMBL ID | CHEMBL4101487 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | J0IIT8QSQS (ChemIDplus, GSRS) |